Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center Phase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor

Next Previous
Search
Trial Profile

An Open-label, Multi-center Phase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Famitinib (Primary)
  • Indications Colon cancer; Colorectal cancer; Rectal cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 10 May 2024 Results from the cohort of advanced NSCLC patients who progressed after treatment with platinum-doublet chemotherapy and immunotherapy, published in the Cancer Immunology Immunotherapy
    • 14 Sep 2023 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2022 Results (n=15) assessing camrelizumab plus famitinib antitumor activity in recurrent or metastatic nasopharyngeal carcinoma patients were presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top